AIDS and Behavior

, Volume 15, Issue 7, pp 1397–1409 | Cite as

Once Daily Dosing Improves Adherence to Antiretroviral Therapy

  • Janet Raboud
  • Maggie Li
  • Sharon Walmsley
  • Curtis Cooper
  • Sandra Blitz
  • Ahmed M. Bayoumi
  • Sean Rourke
  • Sergio Rueda
  • Anita Rachlis
  • Nicole Mittmann
  • Marek Smieja
  • Evan Collins
  • Mona R. Loutfy
Original Paper

Abstract

We studied the association of once-daily dosing with self-reported adherence among participants of the Ontario Cohort Study who were currently taking ART and who had completed a 90-min interviewer-administered questionnaire. Suboptimal adherence was defined as missing ≥1 dose of ART in the 4 days prior to the interview. Participants (n = 779) were 85% male, 69% men having sex with men, 67% white, median age 48 years (IQR 42–54), median years of ART 9 (IQR 5–13) and median CD4 count 463 cells/mm3 (IQR 320–638). Fifteen percent of participants reported suboptimal adherence in the 4 days prior to the interview. In a multivariable logistic regression model, participants on once daily regimens were half as likely to miss a dose during the 4 days prior to the interview. Other independent correlates of suboptimal adherence were younger age, lower positive social interaction and increased frequency of consuming > 6 alcoholic drinks on one occasion.

Keywords

Adherence HIV Antiretroviral therapy Once-daily dosing 

References

  1. 1.
    Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMedGoogle Scholar
  2. 2.
    Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108–14.PubMedCrossRefGoogle Scholar
  3. 3.
    Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3):266–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS. 2008;22:2371–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrobial Chemother. 2008;61(4):769–73.CrossRefGoogle Scholar
  7. 7.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1–161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 1 Apr 2010.
  8. 8.
    Plankey M, Bacchetti P, Jin C, et al. Self perception of body fat changes and HAART adherence in the women’s interagency HIV study. AIDS Behav. 2009;13(1):53–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Turner RJ, Wheaton B, Lloyd DA. The epidemiology of social stress. Am Sociol Rev. 1995;60(1):104–25.CrossRefGoogle Scholar
  10. 10.
    Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19–25.PubMedGoogle Scholar
  11. 11.
    Malta M, Magnanini MM, Strathdee S, Bastos FI. Adherence to Antiretroviral Therapy among HIV infected Drug users: A Meta Analysis. AIDS Behav. 2010;14(4):731–47.PubMedCrossRefGoogle Scholar
  12. 12.
    Cardarelli R, Weis S, Adams E, et al. General health status and adherence to antiretroviral therapy. J Int Assoc Physicians AIDS Care. 2008;7:123–9.CrossRefGoogle Scholar
  13. 13.
    Merenstein DJ, Schneider MF, Cox C, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women’s Interagency HIV Study. Pediatrics. 2008;121(4):e787–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Boer-van De, der Kolk M, Sprangers MAG, van der Ende M, Schreij G, de Wolf F, Nieuwkerk PT. Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort. JAIDS. 2008;49:460–1.CrossRefGoogle Scholar
  15. 15.
    Gonzalez JS, Penedo FJ, Llabre MM, et al. Physical symptoms, beliefs about medications, negative mood, long-term HIV medication adherence. Ann Behav Med. 2007;34(1):46–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Moody KA, Ebrahim D, Deschamps AED, De Geest S, Spirig R. The Relationship of Symptom Experience and Nonadherence in HIV. 3rd International Conference on HIV Treatment Adherence, March 17–18, 2008 Jersey City, NJ.Google Scholar
  17. 17.
    Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder. AIDS Behav. 2009;13(1):60–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Leserman J, Ironson G, O’Cleirigh C, Fordiani JM, Balbin E. Stressful life events and adherence in HIV. AIDS Patient Care STDs. 2008;22(5):403–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRefGoogle Scholar
  20. 20.
    Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Cruess DG, Petitto JM, Leserman J, et al. Depression and HIV infection: impact on immune function and disease progression. CNS Spectrosc. 2003;8:52–8.Google Scholar
  22. 22.
    Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418–28.PubMedCrossRefGoogle Scholar
  23. 23.
    Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Bogart LM, Wagner G, Galvan FH, Banks D. Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV. J Acquir Immune Defic Syndr. 2010;53(5):648–55.PubMedGoogle Scholar
  25. 25.
    Sayles JN, Wong MD, Kinsler JJ, Martins D, Cunningham WE. The association of stigma with self-reported access to medical care and antiretroviral therapy adherence in persons living with HIV/AIDS. J Gen Intern Med. 2009;24(10):1101–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Pope H, White D, Cherry C, et al. The association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence. J Int Assoc Physicians AIDS Care. 2008;7:317.Google Scholar
  27. 27.
    Brion JM, Menke EM, et al. Perspectives regarding adherence to prescribed treatment in highly adherent HIV-infected gay men. J Assoc Nurses AIDS Care. 2008;19(3):181–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Horberg MA, Tang B, Towner WJ, et al. Two versus three pills daily HAART—does it make a difference? 3rd International conference on HIV treatment adherence, March 17–18, 2008 Jersey City, NJ.Google Scholar
  29. 29.
    Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of antiretroviral regimen, and plasma HIV Type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to a once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining virologic suppression. HIV Clin Trials. 2008;9:164–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Molina JM, Podsadecki TJ, Johnson MA, et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505–14.PubMedCrossRefGoogle Scholar
  32. 32.
    Jayaweera D, Dejesus E, Nguyen KL, Grimm K, Butcher D, Seekins DW. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks. HIV Clin Trials. 2009;10(6):375–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Cooper V, Horne R, Gellaitry G, et al. The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based haart over 48 weeks: the NOCTE study. JAIDS. 2010;53(3):369–77.PubMedCrossRefGoogle Scholar
  34. 34.
    Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ, Epivir-Ziagen (EZ) Switch Study Team. Switching from twice-daily abacavir and lamivudine to the once daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9:667–92.PubMedCrossRefGoogle Scholar
  35. 35.
    Parienti JJ, Massari V, Reliquet V, et al. Effect of twice-daily nevirapine on adherence in HIV-1 infected patients: a randomized controlled study. AIDS. 2007;21:2217–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIV positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Bangsberg DR, Ragland K, Monk A, Deeks SG. A one-pill, once-daily, fixed-dose combination (FDC) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (EFV/FTC/TDF) regimen is associated with higher unannounced pill count adherence than non-one pill, once daily. Conference on Retroviruses and Opportunistic Infections, San Francisco 2010.Google Scholar
  38. 38.
    Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.CrossRefGoogle Scholar
  41. 41.
    Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med. 1997;4(1):92–100.PubMedCrossRefGoogle Scholar
  42. 42.
    Carver CS, Scheier MF, Weintraub KJ. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989;56(2):267–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Pearlin LI, Schooler C. The structure of coping. J Health Soc Behav. 1978;19(1):2–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Janet Raboud
    • 1
    • 2
  • Maggie Li
    • 1
  • Sharon Walmsley
    • 1
    • 3
  • Curtis Cooper
    • 4
  • Sandra Blitz
    • 1
  • Ahmed M. Bayoumi
    • 3
    • 5
  • Sean Rourke
    • 3
    • 5
    • 6
    • 7
  • Sergio Rueda
    • 5
    • 6
  • Anita Rachlis
    • 3
    • 8
  • Nicole Mittmann
    • 9
  • Marek Smieja
    • 10
  • Evan Collins
    • 1
    • 7
  • Mona R. Loutfy
    • 3
    • 11
    • 12
  1. 1.Division of Infectious DiseaseUniversity Health NetworkTorontoCanada
  2. 2.Dalla Lana School of Public HealthUniversity of TorontoTorontoCanada
  3. 3.Departments of Medicine and Health PolicyManagement and Evaluation, University of TorontoTorontoCanada
  4. 4.The University of Ottawa, The Ottawa Hospital Division of Infectious DiseasesOttawaCanada
  5. 5.Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge Institute and Division of General Internal MedicineSt. Michael’s HospitalTorontoCanada
  6. 6.Ontario HIV Treatment NetworkTorontoCanada
  7. 7.Department of PsychiatryUniversity of TorontoTorontoCanada
  8. 8.Division of Infectious DiseasesSunnybrook Health Sciences CentreTorontoCanada
  9. 9.Health Outcomes and Pharmaco Economics (HOPE) Research CentreSunnybrook Health Sciences CentreTorontoCanada
  10. 10.Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada
  11. 11.Maple Leaf Medical ClinicTorontoCanada
  12. 12.Women’s College Research InstituteWomen’s College HospitalTorontoCanada

Personalised recommendations